(Q43068334)

English

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

scientific article published on 8 May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 November 2017

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes (English)

1 reference

Europe PubMed Central

13 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

13 November 2017

7

object named as

Jacek Jassem

1 reference

Europe PubMed Central

13 November 2017

Gabriel N Hortobagyi

1

object named as

Gabriel N Hortobagyi

1 reference

Europe PubMed Central

13 November 2017

6

object named as

Valorie F Chan

1 reference

Europe PubMed Central

13 November 2017

Guillermo L Lerzo

8

object named as

Guillermo L Lerzo

1 reference

Europe PubMed Central

13 November 2017

Fernando Hurtado de Mendoza

10

object named as

Fernando Hurtado de Mendoza

1 reference

Europe PubMed Central

13 November 2017

5

object named as

Luis E Fein

1 reference

Europe PubMed Central

13 November 2017

13

object named as

Ronald A Peck

1 reference

Europe PubMed Central

13 November 2017

author name string

Henry L Gomez

2

1 reference

Europe PubMed Central

13 November 2017

Rubi K Li

3

1 reference

Europe PubMed Central

13 November 2017

Hyun-Cheol Chung

4

1 reference

Europe PubMed Central

13 November 2017

Xavier B Pivot

9

1 reference

Europe PubMed Central

13 November 2017

Binghe Xu

11

1 reference

Europe PubMed Central

13 November 2017

Pralay Mukhopadhyay

14

1 reference

Europe PubMed Central

13 November 2017

Henri H Roché

15

1 reference

Europe PubMed Central

13 November 2017

language of work or name

0 references

publication date

8 May 2010

1 reference

Europe PubMed Central

13 November 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

13 November 2017

122

1 reference

Europe PubMed Central

13 November 2017

2

1 reference

Europe PubMed Central

13 November 2017

409-418

1 reference

Europe PubMed Central

13 November 2017

https://scigraph.springernature.com/pub.10.1007/s10549-010-0901-4

0 references

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Gr

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Molecular mechanisms of drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Facts and controversies in systemic treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Assessing the measure of a new drug: is survival the only thing that matters?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Is breast cancer survival improving?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Single agent versus combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Endpoints for assessing drug activity in clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0901-4

21 January 2018

Identifiers

10.1007/S10549-010-0901-4

1 reference

Europe PubMed Central

13 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

13 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43068334&oldid=2119133489"